2025 Q2 -tulosraportti
192 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 4 000 | - | - | ||
| 53 491 | - | - | ||
| 5 000 | - | - | ||
| 50 000 | - | - |
Ylin
3,41VWAP
Alin
3,08VaihtoMäärä
32,6 10 069 162
VWAP
Ylin
3,41Alin
3,08VaihtoMäärä
32,6 10 069 162
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sittenHappy Sunday. Like Clausen, I want to inform new shareholders who have not properly familiarized themselves with the case about links to articles that were presented at the press conference on March 3rd; The strategy to raise Circio´s profile and circular RNA awareness was initiated in 2024, following in vivo validation of Circio´s unique and powerful circVec expression system. Over the past year, this effort has resulted in 57 published articles in 33 key life science industry publications, including three in-depth podcast interviews, covering recent partnerships, with Certest Biotec and 4basebio, and the launch of the latest circVec generation 3.0. These publications and podcasts have a combined biopharma following of 14 million stakeholders across the biopharma sector from biotech and pharma executives and investors to academic scientists, regulators, and policy think-tanks. Direct link to the page for the articles: https://www.circio.com/en/circios-leading-position-in-circular-rna-therapeutics-highlighted-by-continued-broad-coverage-in-international-life-science-industry-media/ The most prominent recent articles and podcasts include: The therapeutic potential of circular RNAs Nature Reviews Genetics, 9 January 2025 Circio’s Vision For Long-Lasting Nucleic Acid Therapeutics InVivo, the Citeline publication, 16 December 2024 Opinion: Circular RNA Will Soon Replace mRNA in Biopharma BioSpace, 31 July 2024 Takeovers, Trump, and trends: how biopharma is likely to shift this year BioXconomy, 1 January 2025 Forecasting Pharma’s Future Drug Solutions podcast, PharmTech, 31 January 2025 Pivoting to RNA with Circio´s Dr. Erik Digman Wiklund Business of Biotech podcast, 2 September 2024 “Since emerging from ‘stealth mode’, we have worked systematically to communicate our position as discoverers and leaders in the rapidly expanding circular RNA field,” said Erik Digman Wiklund, CEO of Circio. “This effort is continuing to bear fruit through a substantial number of articles and podcasts in industry media featuring Circio, as demonstrated in particular by the invitation to review the circular RNA therapeutics field in the prestigious scientific journal Nature Reviews Genetics. The broad coverage across multiple channels builds important visibility and validation for the circVec platform and its significant potential over conventional mRNA-based expression technology.” Everything indicates high exposure in the field. Have a good week!
·1 päivä sittenSince we have gained many new shareholders this week, I thought I would attach a fantastic 10-minute interview from January 26th with CEO Erik Digman Wiklund, which I would recommend people watch over the weekend :) Lots of potential in Circio! 🤩 https://biostock.se/en/2026/01/circios-vd-om-emission-big-pharma-avtal-och-vagen-framat/·11 t sittenVery exciting and good that you post it, as there are probably quite a few new people here. I think we got quite a few new owners in the last 2 days; it suddenly went quiet from people who wrote 'rockets'. Quite a few traders probably threw in the towel now that we had two small red days. So I hope some of the new owners of the shares familiarize themselves with what they have bought and believe in the company and don't just look at the price hour by hour. But we'll see if a collaboration agreement comes eventually. When that comes, I have no idea, but I would imagine they are working on things now that they have received a lot of positive publicity and attention. So I'm quite confident that someone will collaborate with circio eventually 😊
·1 päivä sittenWhat an awesome week, seems like someone is buying all shares when the dips come! Very excited for the 20 list. Next 4 weeks I think will be totally awesome, good weekend!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
192 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenHappy Sunday. Like Clausen, I want to inform new shareholders who have not properly familiarized themselves with the case about links to articles that were presented at the press conference on March 3rd; The strategy to raise Circio´s profile and circular RNA awareness was initiated in 2024, following in vivo validation of Circio´s unique and powerful circVec expression system. Over the past year, this effort has resulted in 57 published articles in 33 key life science industry publications, including three in-depth podcast interviews, covering recent partnerships, with Certest Biotec and 4basebio, and the launch of the latest circVec generation 3.0. These publications and podcasts have a combined biopharma following of 14 million stakeholders across the biopharma sector from biotech and pharma executives and investors to academic scientists, regulators, and policy think-tanks. Direct link to the page for the articles: https://www.circio.com/en/circios-leading-position-in-circular-rna-therapeutics-highlighted-by-continued-broad-coverage-in-international-life-science-industry-media/ The most prominent recent articles and podcasts include: The therapeutic potential of circular RNAs Nature Reviews Genetics, 9 January 2025 Circio’s Vision For Long-Lasting Nucleic Acid Therapeutics InVivo, the Citeline publication, 16 December 2024 Opinion: Circular RNA Will Soon Replace mRNA in Biopharma BioSpace, 31 July 2024 Takeovers, Trump, and trends: how biopharma is likely to shift this year BioXconomy, 1 January 2025 Forecasting Pharma’s Future Drug Solutions podcast, PharmTech, 31 January 2025 Pivoting to RNA with Circio´s Dr. Erik Digman Wiklund Business of Biotech podcast, 2 September 2024 “Since emerging from ‘stealth mode’, we have worked systematically to communicate our position as discoverers and leaders in the rapidly expanding circular RNA field,” said Erik Digman Wiklund, CEO of Circio. “This effort is continuing to bear fruit through a substantial number of articles and podcasts in industry media featuring Circio, as demonstrated in particular by the invitation to review the circular RNA therapeutics field in the prestigious scientific journal Nature Reviews Genetics. The broad coverage across multiple channels builds important visibility and validation for the circVec platform and its significant potential over conventional mRNA-based expression technology.” Everything indicates high exposure in the field. Have a good week!
- ·1 päivä sittenSince we have gained many new shareholders this week, I thought I would attach a fantastic 10-minute interview from January 26th with CEO Erik Digman Wiklund, which I would recommend people watch over the weekend :) Lots of potential in Circio! 🤩 https://biostock.se/en/2026/01/circios-vd-om-emission-big-pharma-avtal-och-vagen-framat/·11 t sittenVery exciting and good that you post it, as there are probably quite a few new people here. I think we got quite a few new owners in the last 2 days; it suddenly went quiet from people who wrote 'rockets'. Quite a few traders probably threw in the towel now that we had two small red days. So I hope some of the new owners of the shares familiarize themselves with what they have bought and believe in the company and don't just look at the price hour by hour. But we'll see if a collaboration agreement comes eventually. When that comes, I have no idea, but I would imagine they are working on things now that they have received a lot of positive publicity and attention. So I'm quite confident that someone will collaborate with circio eventually 😊
- ·1 päivä sittenWhat an awesome week, seems like someone is buying all shares when the dips come! Very excited for the 20 list. Next 4 weeks I think will be totally awesome, good weekend!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 4 000 | - | - | ||
| 53 491 | - | - | ||
| 5 000 | - | - | ||
| 50 000 | - | - |
Ylin
3,41VWAP
Alin
3,08VaihtoMäärä
32,6 10 069 162
VWAP
Ylin
3,41Alin
3,08VaihtoMäärä
32,6 10 069 162
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
192 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sittenHappy Sunday. Like Clausen, I want to inform new shareholders who have not properly familiarized themselves with the case about links to articles that were presented at the press conference on March 3rd; The strategy to raise Circio´s profile and circular RNA awareness was initiated in 2024, following in vivo validation of Circio´s unique and powerful circVec expression system. Over the past year, this effort has resulted in 57 published articles in 33 key life science industry publications, including three in-depth podcast interviews, covering recent partnerships, with Certest Biotec and 4basebio, and the launch of the latest circVec generation 3.0. These publications and podcasts have a combined biopharma following of 14 million stakeholders across the biopharma sector from biotech and pharma executives and investors to academic scientists, regulators, and policy think-tanks. Direct link to the page for the articles: https://www.circio.com/en/circios-leading-position-in-circular-rna-therapeutics-highlighted-by-continued-broad-coverage-in-international-life-science-industry-media/ The most prominent recent articles and podcasts include: The therapeutic potential of circular RNAs Nature Reviews Genetics, 9 January 2025 Circio’s Vision For Long-Lasting Nucleic Acid Therapeutics InVivo, the Citeline publication, 16 December 2024 Opinion: Circular RNA Will Soon Replace mRNA in Biopharma BioSpace, 31 July 2024 Takeovers, Trump, and trends: how biopharma is likely to shift this year BioXconomy, 1 January 2025 Forecasting Pharma’s Future Drug Solutions podcast, PharmTech, 31 January 2025 Pivoting to RNA with Circio´s Dr. Erik Digman Wiklund Business of Biotech podcast, 2 September 2024 “Since emerging from ‘stealth mode’, we have worked systematically to communicate our position as discoverers and leaders in the rapidly expanding circular RNA field,” said Erik Digman Wiklund, CEO of Circio. “This effort is continuing to bear fruit through a substantial number of articles and podcasts in industry media featuring Circio, as demonstrated in particular by the invitation to review the circular RNA therapeutics field in the prestigious scientific journal Nature Reviews Genetics. The broad coverage across multiple channels builds important visibility and validation for the circVec platform and its significant potential over conventional mRNA-based expression technology.” Everything indicates high exposure in the field. Have a good week!
- ·1 päivä sittenSince we have gained many new shareholders this week, I thought I would attach a fantastic 10-minute interview from January 26th with CEO Erik Digman Wiklund, which I would recommend people watch over the weekend :) Lots of potential in Circio! 🤩 https://biostock.se/en/2026/01/circios-vd-om-emission-big-pharma-avtal-och-vagen-framat/·11 t sittenVery exciting and good that you post it, as there are probably quite a few new people here. I think we got quite a few new owners in the last 2 days; it suddenly went quiet from people who wrote 'rockets'. Quite a few traders probably threw in the towel now that we had two small red days. So I hope some of the new owners of the shares familiarize themselves with what they have bought and believe in the company and don't just look at the price hour by hour. But we'll see if a collaboration agreement comes eventually. When that comes, I have no idea, but I would imagine they are working on things now that they have received a lot of positive publicity and attention. So I'm quite confident that someone will collaborate with circio eventually 😊
- ·1 päivä sittenWhat an awesome week, seems like someone is buying all shares when the dips come! Very excited for the 20 list. Next 4 weeks I think will be totally awesome, good weekend!
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 30 | - | - | ||
| 4 000 | - | - | ||
| 53 491 | - | - | ||
| 5 000 | - | - | ||
| 50 000 | - | - |
Ylin
3,41VWAP
Alin
3,08VaihtoMäärä
32,6 10 069 162
VWAP
Ylin
3,41Alin
3,08VaihtoMäärä
32,6 10 069 162
Välittäjätilasto
Dataa ei löytynyt